{"id":"NCT00474058","sponsor":"UCB Pharma","briefTitle":"Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine","officialTitle":"Phase 3B, Multicenter, Multinational, Double-Blind, Placebo Controlled, 2-Arm Trial to Evaluate the Effect of the 24-Hour Transdermal Delivery of Rotigotine on the Control of Early Morning Motor Function, Sleep Quality, Nocturnal Symptoms, and Non-Motor Symptoms in Subjects With Idiopathic Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2007-05-16","resultsPosted":"2010-04-12","lastUpdate":"2015-06-22"},"enrollment":287,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Rotigotine","otherNames":["Neupro"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rotigotine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.","primaryOutcome":{"measure":"Change in Early Morning UPDRS Part III Score","timeFrame":"From baseline to end of maintenance (after 4 weeks maintenance)","effectByArm":[{"arm":"Rotigotine","deltaMin":-7,"sd":7.6},{"arm":"Placebo","deltaMin":-3.9,"sd":7.3}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":47,"countries":["United States","Australia","Austria","Finland","Germany","Hungary","Italy","New Zealand","Poland","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["21790503","24602411","24457253","21322021"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":191},"commonTop":["Nausea","Dizziness","Dyskinesia","Headache"]}}